UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 ORor 15(d) ~~of The Securities Exchange Act of 1934~~

~~February~~of ~~18,~~the ~~2026~~Securities Exchange Act of 1934

Date of ~~report~~Report (Date of earliest event reported): February 26, 2026

Bausch Health Companies Inc.

(Exact name of registrant as specified in its charter)

British Columbia

Canada

001-14956

98-0448205

British Columbia, Canada

001-14956

98-0448205

(State or other jurisdiction of incorporation)

(Commission file number)

(IRS Employer Identification No.)

(State or other jurisdictionof incorporation or organization)

(CommissionFile Number)

(I.R.S. EmployerIdentification Number)

2150 St. Elzéar Blvd. West~~, Laval, Québec, Canada H7L 4A8~~

Laval, Quebec

Canada H7L 4A8

(Address of Principal Executive Offices) (Zip Code)

(514) -744-6792

(Registrant'’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class ~~Trading Symbol~~TradingSymbol(s) Name of each ~~exchange~~exchangeon on which registered Common Shares, No Par Value BHC New York Stock Exchange Toronto Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act~~. ☐~~

Item 25.02~~. Results~~ Departure of ~~Operations~~Directors ~~and~~or ~~Financial~~Certain ~~Condition.~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On February 1826, 2026, Bausch Health Companies Inc., ~~issued~~(the a“Company”) ~~press~~took ~~release~~actions ~~announcing~~to ~~results~~provide ~~of operations~~ for ~~the~~certain ~~quarter~~earned ~~and~~2023 ~~the~~performance ~~year~~share ~~ended~~unit ~~December 31,~~awards ~~2025~~(“2023 ~~and~~PSUs”) ~~certain~~to ~~other~~be ~~financial~~paid ~~information~~in ascash ofrather ~~and~~than ~~for~~stock ~~the~~upon ~~quarter and the year ended December 31~~vesting, ~~2025.~~including Afor ~~copy~~named ofexecutive ~~the~~officers ~~press~~Thomas ~~release~~Appio isand ~~attached~~Seana ~~as Exhibit 99~~Carson.1 toThe ~~this~~2023 ~~report~~PSUs ~~and~~were isoriginally ~~incorporated~~granted ~~herein~~in byMarch ~~this~~2023, ~~reference.~~earned ~~This~~over ~~Current~~a ~~Report~~three-year onperformance ~~Form~~period ~~8-K~~ and ~~the~~scheduled ~~press~~to ~~release~~vest ~~attached~~on ~~hereto~~March 3, as2026 ~~Exhibit 99.1 do not constitute an offer to sell or~~ (the ~~solicitation~~“Vesting ~~of an offer to buy any securities~~Date”).

The ~~information~~Talent inand ~~this~~Compensation ~~Item~~Committee ~~2.02,~~(the ~~including~~“Committee”) ~~Exhibit~~of ~~99.1,~~the isBoard ~~being~~of ~~furnished~~Directors of the Company amended and ~~shall~~restated ~~not~~the beaward ~~deemed~~agreement applicable to 1,137,862 2023 PSUs for Mr. Appio (the “~~filed~~Appio Agreement”) ~~for~~to provide that the ~~purposes~~2023 PSUs will be settled solely in an amount of ~~Section~~cash 18equal to the market price of the ~~Securities~~Company ~~Exchange~~common ~~Act~~stock earned in respect of ~~1934~~the award, asdetermined ~~amended,~~based oron ~~otherwise~~the ~~subject~~closing toprice of the ~~liabilities~~Company ofcommon ~~that~~stock ~~Section.~~on ~~The~~the ~~information~~Vesting inDate ~~this~~(the ~~Item~~“Market 2Price”).02 The Committee also authorized, and ~~Exhibit~~the 99Company entered into, an agreement with Ms.1 Carson ~~shall~~(the ~~not~~“Carson beAgreement”) ~~incorporated~~pursuant to which, as contemplated by ~~reference~~paragraph ~~into~~7(1)(b) ~~any~~of ~~registration~~the ~~statement~~Income orTax ~~other~~Act ~~document~~(Canada), ~~pursuant~~Ms. Carson agrees to irrevocably dispose of, transfer, assign and surrender to the ~~Securities~~Company ~~Act~~all of ~~1933~~her right, astitle ~~amended~~and interest in and to her 137,922 2023 PSUs in exchange for solely an amount of cash, equal to the Market Price.

~~Item~~The ~~9.01. Financial~~foregoing ~~Statements~~descriptions of the Appio Agreement and ~~Exhibits~~Carson Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of such agreements, which will be filed in the Form 10-Q for the quarter ending on March 31, 2026 and are incorporated by reference into this Item 5.02.

(d) Exhibits

Exhibit No.						Description
99.1						Press Release of Bausch Health Companies Inc., respecting financial results for the fourth quarter and year ended December 31, 2025, dated February 18, 2026
101.SCH						XBRL Taxonomy Extension Schema Document
101.LAB						XBRL Taxonomy Extension Label Linkbase Document
101.PRE						XBRL Taxonomy Extension Presentation Linkbase Document
104						Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

____________________________________

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~Date~~BAUSCH HEALTH COMPANIES INC. By: ~~February 18~~/s/ Kathleen B. Fitzpatrick Name: Kathleen B. Fitzpatrick Title: Executive Vice President, ~~2026~~Chief Human Resources and Communications Officer

~~BAUSCH HEALTH COMPANIES INC. By~~Date: ~~/s/ JEAN-JACQUES CHARHON Jean-Jacques Charhon Executive Vice President~~March 2, ~~Chief Financial Officer (Principal Financial Officer)~~2026

Filing Compare · Bausch Health Companies Inc.